Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
Marco ValgimigliEnrico FrigoliDik HegJan TijssenPeter JüniPascal VranckxYukio OzakiMarie-Claude MoriceBernard ChevalierYoshinobu OnumaStephan WindeckerPim A L ToninoMarco RoffiMaciej LesiakFelix MahfoudJozef BartunekDavid Hildick-SmithAntonio ColomboGoran StankovićAndrés IñiguezCarl SchultzRan KornowskiPaul J L OngMirvat AlasnagAlfredo E RodriguezAris MoschovitisPeep LaanmetsMichael DonahueSergio LeonardiPieter C Smitsnull nullPublished in: The New England journal of medicine (2021)
One month of dual antiplatelet therapy was noninferior to the continuation of therapy for at least 2 additional months with regard to the occurrence of net adverse clinical events and major adverse cardiac or cerebral events; abbreviated therapy also resulted in a lower incidence of major or clinically relevant nonmajor bleeding. (Funded by Terumo; MASTER DAPT ClinicalTrials.gov number, NCT03023020.).
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- atrial fibrillation
- st segment elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- risk assessment
- st elevation myocardial infarction
- subarachnoid hemorrhage
- risk factors
- left ventricular
- adverse drug
- stem cells
- blood brain barrier
- brain injury
- coronary artery bypass